Literature DB >> 12237250

Augmentation of allergic inflammation in prostanoid IP receptor deficient mice.

Yoshimasa Takahashi1, Shota Tokuoka, Taisei Masuda, Yousuke Hirano, Masafumi Nagao, Hiroyuki Tanaka, Naoki Inagaki, Shuh Narumiya, Hiroichi Nagai.   

Abstract

1 To evaluate the role of prostaglandin I(2) (PGI(2)) in allergic inflammation, allergic responses in the airway, skin and T cells were studied in mice lacking the receptor for PGI(2) (the prostanoid IP receptor) through gene disruption. 2 Three inhalations of antigen caused an increase in plasma extravasation, leukocyte accumulation and cytokine (interleukin (IL)-4 and IL-5) production in the airway of sensitized mice. These airway inflammatory responses were significantly greater in IP receptor deficient mice than in wild-type mice. 3 The vascular leakage caused by passive cutaneous anaphylaxis, substance P and 5-hydroxytryptamine was markedly increased in the skin of IP receptor deficient mice, compared with comparably treated wild-type mice. 4 The inhalation of antigen in sensitized mice resulted in increased serum antigen specific IgE, total IgE and IgG levels. The magnitude of the elevations of each immunoglobulin level in IP receptor deficient mice is notably higher than that in wild-type mice. To elucidate the mechanism of an enhancement of immunoglobulin production, the activity of T cells in sensitized and non-sensitized mice was studied by means of the production of cytokines. The antigen-induced IL-4 production by spleen cells from sensitized IP receptor deficient mice was almost three times greater than that in wild-type mice. On the contrary, the anti-CD3 antibody-induced interferon-gamma production by CD4(+) T cells from non-sensitized IP receptor deficient mice was significantly lower than that in wild-type mice. 5 The present data indicate that IP receptor deficiency reinforced an allergic airway and skin inflammation by augmentation of vascular permeability increase and the T helper 2 cell function. These findings suggest a regulatory role of PGI(2) in allergic inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237250      PMCID: PMC1573495          DOI: 10.1038/sj.bjp.0704872

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Dietary nucleic acids and Th1/Th2 balance: a clue to cow's milk allergy?

Authors:  P C Calder
Journal:  Clin Exp Allergy       Date:  2000-07       Impact factor: 5.018

2.  Effect of overproduction of interleukin 5 on dinitrofluorobenzene-induced allergic cutaneous response in mice.

Authors:  H Nagai; Y Ueda; H Tanaka; Y Hirano; N Nakamura; N Inagaki; K Takatsu; K Kawada
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

3.  Involvement of thromboxane A2 and histamine in experimental allergic rhinitis of guinea pigs.

Authors:  M Yamasaki; T Matsumoto; S Fukuda; T Nakayama; H Nagaya; Y Ashida
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

4.  Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets.

Authors:  K Tanaka; K Ogawa; K Sugamura; M Nakamura; S Takano; K Nagata
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

5.  Prostacyclin counteracts the increase in capillary permeability induced by tumour necrosis factor-alpha.

Authors:  J Jahr; P O Grände
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

6.  Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses.

Authors:  P Kaliński; C M Hilkens; A Snijders; F G Snijdewint; M L Kapsenberg
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

7.  Prostaglandin D2 as a mediator of allergic asthma.

Authors:  T Matsuoka; M Hirata; H Tanaka; Y Takahashi; T Murata; K Kabashima; Y Sugimoto; T Kobayashi; F Ushikubi; Y Aze; N Eguchi; Y Urade; N Yoshida; K Kimura; A Mizoguchi; Y Honda; H Nagai; S Narumiya
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

8.  Altered pain perception and inflammatory response in mice lacking prostacyclin receptor.

Authors:  T Murata; F Ushikubi; T Matsuoka; M Hirata; A Yamasaki; Y Sugimoto; A Ichikawa; Y Aze; T Tanaka; N Yoshida; A Ueno; S Oh-ishi; S Narumiya
Journal:  Nature       Date:  1997-08-14       Impact factor: 49.962

9.  Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation.

Authors:  G M Gauvreau; R M Watson; P M O'Byrne
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

10.  Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness.

Authors:  C Y Wu; K Wang; J F McDyer; R A Seder
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

View more
  38 in total

1.  Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function.

Authors:  Marco Idzko; Hamida Hammad; Menno van Nimwegen; Mirjam Kool; Nanda Vos; Henk C Hoogsteden; Bart N Lambrecht
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

2.  PGI2 Controls Pulmonary NK Cells That Prevent Airway Sensitization to House Dust Mite Allergen.

Authors:  Bryan Simons; Maria E Ferrini; Sophia Carvalho; David J P Bassett; Zeina Jaffar; Kevan Roberts
Journal:  J Immunol       Date:  2016-11-28       Impact factor: 5.422

3.  Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension.

Authors:  Robert S Stearman; Amber R Cornelius; Xiao Lu; David S Conklin; Mark J Del Rosario; Anita M Lowe; Mihret T Elos; Lynsey M Fettig; Randall E Wong; Naoko Hara; Joy D Cogan; John A Phillips; Matthew R Taylor; Brian B Graham; Rubin M Tuder; James E Loyd; Mark W Geraci
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

4.  Prostaglandin I2 signaling licenses Treg suppressive function and prevents pathogenic reprogramming.

Authors:  Allison E Norlander; Melissa H Bloodworth; Shinji Toki; Jian Zhang; Weisong Zhou; Kelli Boyd; Vasiliy V Polosukhin; Jacqueline-Yvonne Cephus; Zachary J Ceneviva; Vivek D Gandhi; Nowrin U Chowdhury; Louis-Marie Charbonnier; Lisa M Rogers; Janey Wang; David M Aronoff; Lisa Bastarache; Dawn C Newcomb; Talal A Chatila; R Stokes Peebles
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

Review 5.  PGI2 as a regulator of CD4+ subset differentiation and function.

Authors:  Madison G Boswell; Weisong Zhou; Dawn C Newcomb; R Stokes Peebles
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-12       Impact factor: 3.072

6.  Deletion of microsomal prostaglandin E synthase-1 does not alter ozone-induced airway hyper-responsiveness.

Authors:  Miao Wang; Philip R Cooper; Meiqi Jiang; Hengjiang Zhao; Yiqun Hui; Yubing Yao; Joshua C Tate; Gautam Damera; John A Lawson; William F Jester; Angela Haczku; Reynold A Panettieri; Garret A FitzGerald
Journal:  J Pharmacol Exp Ther       Date:  2010-04-06       Impact factor: 4.030

Review 7.  Prostanoids and inflammation: a new concept arising from receptor knockout mice.

Authors:  Shuh Narumiya
Journal:  J Mol Med (Berl)       Date:  2009-07-17       Impact factor: 4.599

8.  Prostaglandin I2 Suppresses Proinflammatory Chemokine Expression, CD4 T Cell Activation, and STAT6-Independent Allergic Lung Inflammation.

Authors:  Weisong Zhou; Jian Zhang; Kasia Goleniewska; Daniel E Dulek; Shinji Toki; Dawn C Newcomb; Jacqueline Y Cephus; Robert D Collins; Pingsheng Wu; Mark R Boothby; R Stokes Peebles
Journal:  J Immunol       Date:  2016-07-25       Impact factor: 5.422

Review 9.  Regulation of T helper cell subsets by cyclooxygenases and their metabolites.

Authors:  Hong Li; Matthew L Edin; Artiom Gruzdev; Jennifer Cheng; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Darryl C Zeldin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-11-28       Impact factor: 3.072

Review 10.  Protease-activated receptors and prostaglandins in inflammatory lung disease.

Authors:  Terence Peters; Peter J Henry
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.